Home / Mumbai / Mumbai News / Article /
Mumbai: Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 crore doses a year
Updated On: 02 June, 2021 02:34 PM IST | Mumbai | ANI
The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR.

A health worker prepares to inoculate a woman with a dose of the Covaxin Covid-19 vaccine. Pic/AFP
Haffkine Bio-Pharmaceutical Corporation Limited (HBPCL), a Maharashtra government undertaking, is preparing for mass production of Covaxin and will have capacity to produce over 22 crore doses of the Covid-19 vaccine every year once the requisite facilities are in place.
The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR. Sandeep Rathod, Managing Director of HBPCL, told ANI that formalities of technology transfer from Bharat Biotech are being completed.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

